Brinton Eliot A
Carl T. Hayden VA Medical Center, Section of Metabolism, Endocrinology, & Nutrition, Department of Internal Medicine, 111 E, 650 East Indian School Road, Phoenix, AZ 85012, USA.
Curr Diab Rep. 2003 Feb;3(1):65-72. doi: 10.1007/s11892-003-0056-3.
The metabolic syndrome is the constellation of adverse metabolic and clinical effects of insulin resistance. Its high and increasing prevalence and its profound impact on the major diseases of the western world require that clinicians consider its diagnosis and management on a routine basis. Recently published guidelines on its definition now make convenient and reliable diagnosis possible. Also, there is new and better understanding of the complex dyslipidemias and other risk factors strongly associated with the metabolic syndrome, which greatly increase the risk of clinical atherosclerotic events. Comprehensive clinical evaluation of these dyslipidemias and associated atherosclerosis risk factors can lead to their aggressive treatment, customized according to the circumstances of each patient. These steps are now more feasible and more clearly desirable than ever before. Statins alone greatly reduce atherosclerosis risk, but combination lipid therapy is often required for optimal dyslipidemia management and atheroprevention.
代谢综合征是胰岛素抵抗所导致的一系列不良代谢和临床效应。其高患病率且呈上升趋势，以及对西方世界主要疾病的深远影响，要求临床医生常规考虑其诊断和管理。最近发布的关于其定义的指南使便捷可靠的诊断成为可能。此外，对于与代谢综合征密切相关的复杂血脂异常和其他危险因素有了新的、更好的认识，这大大增加了临床动脉粥样硬化事件的风险。对这些血脂异常和相关动脉粥样硬化危险因素进行全面的临床评估，可根据每位患者的具体情况进行积极治疗。现在，这些步骤比以往任何时候都更可行且更具必要性。仅使用他汀类药物可大大降低动脉粥样硬化风险，但对于血脂异常的最佳管理和动脉粥样硬化预防，通常需要联合降脂治疗。
